Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
FHTX 
Foghorn Therapeutics Inc (FHTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/14/2025: FHTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $10.57
1 Year Target Price $10.57
| 5 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -72.84% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 301.00M USD | Price to earnings Ratio - | 1Y Target Price 10.57 |
Price to earnings Ratio - | 1Y Target Price 10.57 | ||
Volume (30-day avg) 8 | Beta 3.05 | 52 Weeks Range 2.94 - 10.25 | Updated Date 07/14/2025 |
52 Weeks Range 2.94 - 10.25 | Updated Date 07/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.29 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -384.96% |
Management Effectiveness
Return on Assets (TTM) -23.12% | Return on Equity (TTM) -470.38% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 115268414 | Price to Sales(TTM) 12.81 |
Enterprise Value 115268414 | Price to Sales(TTM) 12.81 | ||
Enterprise Value to Revenue 4.9 | Enterprise Value to EBITDA -1.21 | Shares Outstanding 55741400 | Shares Floating 25974922 |
Shares Outstanding 55741400 | Shares Floating 25974922 | ||
Percent Insiders 18.95 | Percent Institutions 72.7 |
Upturn AI SWOT
Foghorn Therapeutics Inc
Company Overview
History and Background
Foghorn Therapeutics Inc. was founded in 2016. The company focuses on discovering and developing therapies targeting genetically determined chromatin dysregulation, a major driver of cancer.
Core Business Areas
- Gene Traffic Controlu00ae Platform: Foghorn's proprietary drug discovery platform, Gene Traffic Controlu00ae, helps identify previously inaccessible cancer targets within the chromatin regulatory system. This platform allows for the creation of drugs against these novel targets.
- Oncology Drug Development: Focus on developing small molecule and protein degrader drugs targeting chromatin regulatory proteins implicated in cancer. The company has several programs in preclinical and clinical development.
Leadership and Structure
Key leadership includes CEO Michael LaCascia, and CSO Kristina Alimova. The company has a board of directors overseeing strategic direction.
Top Products and Market Share
Key Offerings
- FOG-001: A highly selective and potent oral inhibitor of BRD9, a core member of non-canonical BAF (ncBAF) complex. Currently in Phase 1 clinical trial for relapsed and/or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Limited market share as it is in clinical trials. Competitors include companies developing other epigenetic modulators and AML/MDS therapies.
- FOG-005: A protein degrader targeting SMARCA2, which is inactive in tumors with SMARCA4 mutations. Currently in a Phase 1 clinical trial. Competitors include other companies developing targeted therapies for SMARCA4-mutant cancers.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with a focus on developing novel therapies for unmet medical needs, particularly in oncology. Epigenetic therapies represent a growing segment.
Positioning
Foghorn Therapeutics is positioned as a leader in chromatin regulatory-based drug discovery and development. Its Gene Traffic Controlu00ae platform gives it a competitive advantage in identifying and drugging novel cancer targets.
Total Addressable Market (TAM)
The total addressable market for cancer therapeutics is estimated to be in the hundreds of billions of dollars. Foghorn is positioned to capture a portion of this market through its targeted therapies.
Upturn SWOT Analysis
Strengths
- Proprietary Gene Traffic Controlu00ae platform
- Novel target identification
- Experienced management team
- Strong intellectual property portfolio
- Focus on chromatin regulation
Weaknesses
- Early stage clinical development
- Dependence on clinical trial success
- High research and development costs
- Relatively small market capitalization compared to established pharmaceutical companies
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline into new indications
- Advancement of clinical programs
- Potential for breakthrough therapies
- Growing interest in epigenetic drug targets
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent challenges
- Changes in the regulatory landscape
Competitors and Market Share
Key Competitors
- EPZM
- CLLS
- DNLI
Competitive Landscape
Foghorn has a leading edge because of its Chromatin discovery platform compared to the other competitors in its category.
Growth Trajectory and Initiatives
Historical Growth: Historical growth will depend on clinical trial progression, partnerships, and financing. Currently no drug approvals as of 2024.
Future Projections: Future growth projections depend on the success of clinical trials and partnerships. Analyst estimates vary.
Recent Initiatives: Advancement of FOG-001 and FOG-005 clinical trials, expansion of the pipeline, and partnerships with larger companies.
Summary
Foghorn Therapeutics is a biopharmaceutical company pioneering a new class of medicines targeting chromatin dysregulation. The company's innovative platform, Gene Traffic Controlu00ae, allows it to discover novel cancer targets, giving it a competitive edge. It currently has promising compounds in Phase 1 clinical trials, representing both a great strength and weakness. Successful clinical trials and strategic partnerships are critical for future growth, however funding challenges remain a constant threat.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Foghorn Therapeutics Investor Relations
- SEC Filings (10-K, 10-Q)
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share data is estimated. Financial data requires real-time access and is unavailable for accurate population.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Foghorn Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2020-10-23 | President, CEO & Director Mr. Adrian H. B. Gottschalk | ||
Sector Healthcare | Industry Biotechnology | Full time employees 112 | Website https://foghorntx.com |
Full time employees 112 | Website https://foghorntx.com | ||
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is also developing therapies for mutant cancers, such as androgen receptor, positive prostate cancer, bladder cancer, Non-Small Cell Lung (NSCLC), as well as various lymphomas and leukemias; melanoma, endometrial, gastric, breast, colorectal, and pancreatic cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.